secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K/A
Filed at:   2023-08-18T23:59:59+00:00
Accession:  0001493152-23-029433
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 1.01, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Evofem Biosciences amends 8-K; annual meeting to vote on 6x share increase to 3B, notes at 8% convertible at $1.25
--------------------------------------------------------------------------------

- Annual meeting on Sep 14, 2023; proposal to amend charter to increase authorized shares from 500M to 3B.
- Notes: 8% interest (12% on default), convertible at $1.25/share, maturity Aug 4, 2026.
- Registration rights agreement requires S-1 filing within 90 days of closing; 2% liquidated damages for delays.
- Record date for meeting set as Aug 7, 2023; auditor ratification and advisory vote on executive comp also on ballot.
- Notes are senior-subordinate obligations of Evofem, not subsidiaries; beneficial ownership limitation of 4.99% (adjustable to 9.99%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315223029433/0001493152-23-029433-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315223029433/form8-ka.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-029433

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer